Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when INGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTate & Lyle shareholders approve Ingredion's all-cash acquisition; close expected H2 2027
Filed July 28, 2026 · Period ending July 28, 2026 · ~1 min read
Key Changes
-
high
Tate & Lyle shareholders voted to approve Ingredion's acquisition of the entire issued share capital through a court-sanctioned scheme of arrangement, satisfying a key closing condition for the transaction announced in June 2026.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
high
The deal is expected to close in the second half of 2027, pending remaining conditions including material antitrust approvals and court sanction of the scheme.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
medium
Shareholders approved the scheme at a court-ordered meeting and passed necessary resolutions at a subsequent general meeting, following the UK scheme of arrangement process that requires both shareholder approval and court sanction.
Item 7.01 — Regulation FD Disclosure verify on EDGAR →
Summary
Ingredion disclosed that Tate & Lyle shareholders approved the company's all-cash acquisition of the UK-based ingredients firm on July 28, 2026. The vote, conducted through a court-ordered meeting and subsequent general meeting, satisfies a critical condition for the transaction originally announced in June 2026.
The approval moves the deal forward under the UK scheme of arrangement process, which requires both shareholder consent and court sanction to become effective. The transaction is now expected to close in the second half of 2027, subject to remaining conditions including material antitrust clearances and court sanction of the scheme.
For Ingredion shareholders, the shareholder approval milestone reduces execution risk but leaves regulatory clearance as the primary gating item. The extended timeline to H2 2027 reflects the complexity of obtaining antitrust approvals for a combination of this scale in the specialty ingredients sector. Investors should monitor regulatory filings and any updates on antitrust review progress as the deal moves through the remaining approval process.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify